Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Vaccination efficacy in patients with hematological malignancies

Current knowledge on whether vaccines are efficacious in patients with hematological malignancies remain limited. Susanne Saussele, MD, University of Heidelberg, Mannheim, Germany, discusses antibody response to vaccination with BNT162b2, mRNA-1273, and ChADOx1 in patients with hematological disorders. Patients who did not produce a sufficient immune response post-vaccination tended to have received Bruton’s tyrosine kinase (BTK) inhibitors such as acalabrutinib or ibrutinib, or immunotherapies such as rituximab. Conversely, all patients with chronic myeloid leukemia (CML) responded well to vaccination. Further research is required to assess the effect of booster vaccines in patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.